Evoke Pharma
EVOK
EVOK was delisted on the 16th of December, 2025.
22 hedge funds and large institutions have $2.56M invested in Evoke Pharma in 2019 Q1 according to their latest regulatory filings, with 6 funds opening new positions, 2 increasing their positions, 4 reducing their positions, and 3 closing their positions.
100% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 3
16% more funds holding
Funds holding: 19 → 22 (+3)
8.42% less ownership
Funds ownership: 18.3% → 9.88% (-8.4%)
50% less repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 4
68% less capital invested
Capital invested by funds: $7.91M → $2.56M (-$5.36M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$228K |
| 2 |
Marshall Wace
London,
United Kingdom
|
+$219K |
| 3 |
VF
Virtu Financial
New York
|
+$187K |
| 4 |
TSS
Two Sigma Securities
New York
|
+$103K |
| 5 |
Acadian Asset Management
Boston,
Massachusetts
|
+$100K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
-$3.5M |
| 2 |
KCM
Knoll Capital Management
Miami,
Florida
|
-$682K |
| 3 |
6CM
683 Capital Management
New York
|
-$283K |
| 4 |
BFM
Boothbay Fund Management
New York
|
-$86.6K |
| 5 |
Morgan Stanley
New York
|
-$16.4K |
EVOK Hedge Fund Activity: Q1 2019 in Review
22 of the 4,633 institutional investors tracked by Wall St. Rank reported a position in Evoke Pharma (EVOK) for Q1 2019, worth a combined $2.56M — down 68% from $7.91M a quarter earlier.
Buyers outnumbered sellers: 6 funds opened new EVOK positions and 3 closed out — a net gain of 3 holders — while 2 added to existing stakes and 4 trimmed.
The largest buyer was Vanguard Group, adding an estimated $228K. The largest seller was Sphera Funds Management, exiting entirely with an estimated $3.5M sold.
- 22 institutional investors held Evoke Pharma (EVOK) as of Q1 2019, up from 19 in Q4 2018.
- Funds reported $2.56M of Evoke Pharma stock for Q1 2019, down 68% quarter-over-quarter.
- 6 funds opened new Evoke Pharma positions in Q1 2019 and 3 closed out, a net change of +3 holders.
- The largest Evoke Pharma buyer in Q1 2019 was Vanguard Group, an estimated $228K added.
- The largest Evoke Pharma seller in Q1 2019 was Sphera Funds Management, an estimated $3.5M sold.
Based on aggregated 13F filings for Q1 2019.